Patents by Inventor Martin BROCH-LIPS

Martin BROCH-LIPS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the treatment of neuromuscular disorders
    Patent number: 11730714
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 22, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20220274938
    Abstract: The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.
    Type: Application
    Filed: June 19, 2020
    Publication date: September 1, 2022
    Applicant: NMD PHARMA A/S
    Inventors: Lars J.S. KNUTSEN, Martin BROCH-LIPS, Martin E COOPER, Marc LABELLE, Thomas Holm PEDERSEN, Dastagiri DUDEKULA, Neerja SARASWAT, Rafiq A TAJ
  • Compounds for use in treating neuromuscular disorders
    Patent number: 10934244
    Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: March 2, 2021
    Assignee: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen
  • Compounds For The Treatment Of Neuromuscular Disorders
    Publication number: 20190183834
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Applicant: NMD PHARMA A/S
    Inventors: Thomas Holm Pedersen, Lars J.S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
  • COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS
    Publication number: 20180099920
    Abstract: The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
    Type: Application
    Filed: June 15, 2016
    Publication date: April 12, 2018
    Applicant: NMD PHARMA APS
    Inventors: Thomas HOLM PEDERSEN, Martin BROCH-LIPS, Claus ELSBORG OLESEN, Marc LABELLE, Ole BÆKGAARD NIELSEN